RXi completes enrollment in Phase I/II of RXI-109 for retinal scarring

RXi Pharmaceuticals Corp. (NASDAQ:RXII) completed enrollment of about 9 patients with advanced wet age-related macular degeneration (AMD) in the Phase I/II Study RXI-109-1501 evaluating once-monthly intravitreal RXI-109 for 4 months to reduce the progression of subretinal fibrosis.

The open-label, dose-escalation, U.S. trial will assess safety and pharmacokinetics. Secondary endpoints will measure changes in lesions through optical coherence tomography (OCT), fluorescein angiography and changes in best corrected visual acuity (BCVA)...